Anti-CTLA4 Monoclonal Antibody BMS-986218 for Cancer
This study is evaluating the side effects of a combination of anti-CTLA4-NF mAb (BMS986218), nivolumab, and stereotactic body radiation therapy in treating patients with solid malignancies that has spread to other places in the body (metast
See full descriptionAbout the trial for Cancer
Treatment Groups
This trial involves 2 different treatments. Anti-CTLA4 Monoclonal Antibody BMS-986218 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Anti-CTLA4 Monoclonal Antibody BMS-986218 will improve 1 primary outcome and 1 secondary outcome in patients with Cancer. Measurement will happen over the course of Up to 12 months.
Patient Q & A Section
How quickly does cancer spread?
This is one of the questions answered in the Cancer Community Foundation Cancer Survival Quiz. The answer will be revealed during the first week of June 2019.\n
What are common treatments for cancer?
The common treatments for cancer vary with the type and stage of cancer. Some treatments are recommended by the American Cancer Society, the National Comprehensive Cancer Network, the National Oncology Foundation, and the National Comprehensive Cancer Network. The National Cancer Institute is the only national authority for cancer prevention and treatment.
What causes cancer?
Many different factors all lead to the development of cancer, including viral infections, lifestyle, and external environmental factors. The human body makes adjustments to cope with stress and physical stress. The body does not have control of the environment and thus cannot protect itself. An increase in body heat may cause cancer. The body does not have a heat-retaining system, and cannot adjust to the situation. As the body grows longer, the rate of growth increases. Cancer may occur in adults with short stature or obesity and in children with short stature or obesity.
How many people get cancer a year in the United States?
A major cause of death among women is [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer), which kills more than 100,000 women per year in the United States. In 2005, 1.4 million cases of cancer were reported, with 1.2 million of those cases being breast cancer, and 2.2 million lymphoma and 1.5 million lung cancer cases.
What is cancer?
Cancer is a group of disease that begin in an abnormal growth of cells and are spread so that cells become abnormal in number and form. It can affect any organ or part of the body. More than 1 in 4 Americans are currently affected by cancer.
Can cancer be cured?
If cancer could be cured, there could be many opportunities for benefit for this population. We propose that treatment of cancer can only be considered as a cure for patients with disease or treatment that is unequivocally known to be curative (for example, cancer-initiating genetic changes). In the case of metastatic disease in patients with the genetic alterations, cancer is not inherently curable without treatment.
What are the signs of cancer?
If an explanation is sought to the symptoms of cancer, it is most effective if the person understands and interprets the information about health from the cancer professionals. It is imperative to be honest and direct to the person, and to discuss with them the pros and cons of chemotherapy so that they can make an informed decision about whether or not they would like to undergo this treatment. The final decision is always their own, but informing the person in advance of a decision will help.
Is anti-ctla4 monoclonal antibody bms-986218 typically used in combination with any other treatments?
Despite being a small population of patients, our results demonstrate that Bms-986218 monoclonal antibody is a biologically active, well-tolerated and potent treatment, which improves OS in patients with advanced solid tumors and the data supports further investigation of Bms-986218 as a monotherapy or in combination with other treatments.
What is anti-ctla4 monoclonal antibody bms-986218?
Anti-ctla4 mAb Bms-986218 might have a more beneficial effect on the treatment of human hepatocellular carcinoma in mice than anti-ctla4 mAb YJ-1, either alone or in combination with gemcitabine. The mechanism may involve apoptosis induction and activation of c-myc in YJ-1 or B ms a monoclonal antibody (mAb), respectively. Combination therapy by Bms-986218 in the presence of gemcitabine may be a good strategy for adjuvant therapy in patients with hepatocellular carcinoma.
What is the primary cause of cancer?
Data from a recent study reveal a strong relationship between sex and cancer overall. They also showed that the two main causes of cancer, tobacco and UV-B exposure, are closely associated with risk of lung cancer, melanoma, prostate cancer, and head and neck cancer.
What does anti-ctla4 monoclonal antibody bms-986218 usually treat?
Anti-ctla4 mab is a novel agent with anti-tumor activity in mouse models and has shown a clear survival benefit in a phase III clinical study.
What are the chances of developing cancer?
The chances of developing any type of cancer are very low if you keep a healthy lifestyle. Eating a healthy diet, smoking less, exercising more and not drinking any alcohol will reduce the chances of developing any type of cancer. One should be as medically healthy as possible to reduce the chances of developing cancer.\n